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The aim of the study was to determine if immunomodulation of host defense with recombinant murine
granulocyte colony-stimulating factor (G-CSF) improves the efficacy of trovafloxacin or moxifloxacin in ab-
scesses containing Bacillus fragilis ATCC 23745 and different Escherichia coli strains varying in virulence.
Treatment of mice inoculated with 107 CFU B. fragilis and 105 CFU low-virulence E. coli with either trova-
floxacin (150 mg/kg/day every 24 hours, days 3 to 7) or moxifloxacin (96 mg/kg/day every 12 hours, days 3 to
7), significantly reduced the number of B. fragilis to 6.9  0.35 and 5.8  0.10 and that of E. coli to 4.9  0.09
and 4.2  0.07 log CFU/abscess for trovafloxacin and moxifloxacin, respectively, compared to controls (B.
fragilis 8.7 and E. coli 7.4 log CFU/abscess) on day 8. Also, moxifloxacin was more potent than trovafloxacin.
Addition of G-CSF prophylaxis (1 g once on day 1) or therapy (1 g/day on days 3 to 7) to fluoroquinolone
treatment did not improve the efficacy of fluoroquinolone therapy alone. The effect of moxifloxacin with or
without G-CSF prophylaxis on abscesses with a virulent hemolytic E. coli strain was also studied. In moxi-
floxacin-treated mice, 75% survived infection compared to 10% of controls. Combining moxifloxacin with
G-CSF prophylaxis significantly decreased survival (30%) compared to moxifloxacin alone. In addition, G-CSF
prophylaxis resulted in a threefold (E. coli) to 100-fold (B. fragilis) increased outgrowth in the abscesses of
surviving mice. In conclusion, the addition of G-CSF to a fluoroquinolone is not advisable since, depending on
the virulence of the E. coli strains, this might detrimentally influence the outcome of therapy.
Intra-abdominal abscesses are persistent infections which, in
the absence of adequate therapy, can be the cause of consid-
erable morbidity and mortality. The conventional treatment of
intra-abdominal abscesses involves percutaneous abscess
drainage in conjunction with an intensive course of antimicro-
bial therapy (11). However, when abscesses are multiple and/or
small, drainage procedures are not always possible and, under
these circumstances, antibiotic treatment alone is the only op-
tion available. Despite improvement in antimicrobial therapy,
therapeutic failure of mixed bacterial infections remains a ma-
jor concern and augmentation of nonspecific host defenses
with immunomodulating agents may provide an adjunctive ap-
proach to manage bacterial abscesses.
Granulocyte colony-stimulating growth factor (G-CSF) is
such an agent and G-CSF has been shown to enhance the
nonspecific host resistance to mixed bacterial infections (3, 10,
26). However, except for a minor beneficial influence of G-
CSF on established Candida abscesses (27), no data are avail-
able regarding the influence of G-CSF on established mixed
bacterial abscesses.
In our laboratory, we have employed a subcutaneous mouse
model to study the treatment of small mixed-infection ab-
scesses (22, 23). The aim of the present study was to investigate
whether immunomodulation of host defenses with recombi-
nant murine G-CSF (rmG-CSF) would improve the efficacy of
trovafloxacin or moxifloxacin treatment of established ab-
scesses in our mouse model. In addition, since the efficacy of
G-CSF against a bacterial infection appears to vary with spe-
cies and severity of the infection (7, 16), we also investigated
the effect of rmG-CSF prophylaxis, with and without moxi-
floxacin treatment, on abscesses induced by combinations of
Bacillus fragilis with different Escherichia coli strains varying in
virulence.
(This study was presented in part at the 44th Interscience
Conference on Antimicrobial Agents and Chemotherapy,
Washington, D.C., 2004, abstr. B-1696, p. 60.)
MATERIALS AND METHODS
Materials. Recombinant murine G-CSF was supplied by Amgen (Thousand
Oaks, CA). Trovafloxacin (Trovan) solution for infusion, containing 5 mg/ml,
was supplied by Pfizer B.V. (Capelle a/d IJssel, The Netherlands) and moxifloxa-
cin (Avelox) solution for infusion, containing 400 mg/250 ml, was supplied by
Bayer B.V. (Mijdrecht, The Netherlands). Wilkens Chalgren (WC) broth, Wilk-
ens Chalgren (WC) agar, and eosin methylene blue (EM) agar all came from
Unipath Ltd. (Haarlem, The Netherlands).
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Bacterial strains. The strains used were B. fragilis ATCC 23745, a low-viru-
lence E. coli strain (ATCC 25922), a virulent hemolytic E. coli strain (ATCC
35218), and a virulent nonhemolytic clinical blood isolate, E. coli B14349. All
strains were first passaged in BALB/c mice by injecting 108 to 109 CFU of
overnight cultures (intraperitoneal). After 24 to 48 h, strains were recovered
from the liver and spleen, cultured on blood agar plates, and standardized
bacterial suspensions were made in brain heart infusion containing 20% glycerol
and stored at 80°C until required. Overnight cultures were obtained by inoc-
ulating 30-ml volumes of WC broth with 0.1 ml of the standardized frozen
bacterial suspensions and incubating aerobically (E. coli) or anaerobically (B.
fragilis) at 37°C for 18 h.
Animals. Female specific-pathogen-free BALB/c mice (Charles River, Maas-
tricht, The Netherlands) weighing 20 to 25 g were used throughout the study. The
cecal contents of male specific-pathogen-free Swiss mice (Charles River) were
used for the production of autoclaved cecal contents as preciously described (24).
All animals received water and food ad libitum. The study was approved by the
Institutional Animal Care and Use Committee of the Erasmus MC University
Medical Center, Rotterdam, The Netherlands.
MICs. The MICs of trovafloxacin and moxifloxacin were determined using the
standard broth microdilution method and inocula of 105 CFU/ml as previously
described (24).
Abscess model. The subcutaneous abscess model described previously (23) was
used. Inocula were prepared by diluting overnight cultures of B. fragilis and an E.
coli strain (ATCC 25922, ATCC 35218, or B14349) in WC broth, which were
then mixed together with autoclaved cecal contents in a volume ratio of 1:1:2.
Final inocula contained 4 mg autoclaved cecal contents (dry weight) and 107
CFU B. fragilis along with 105 CFU E. coli ATCC 25922 or E. coli B14349 or 103
E. coli ATCC 35218 in a total volume of 0.25 ml. Mice were injected subcuta-
neously on both flanks. Abscesses were allowed to develop for 1 to 14 days.
Treatment regimens of established abscesses. Abscesses were induced with B.
fragilis and the low-virulence E. coli strain. To determine the effect of rmG-CSF
with or without fluoroquinolone therapy on established abscesses, groups of four
to six mice were injected subcutaneously with 1,000 ng (50 g/kg) rmG-CSF in
100 l pyrogen-free saline. Injections were given as a single dose 24 h before
inoculation (rmG-CSF prophylaxis) or five daily doses given 3 to 7 days after
inoculation (rmG-CSF therapy). Subgroups receiving antibiotic therapy were
treated for 5 days (day 3 to day 7 after inoculation) with single daily doses of
trovafloxacin at 150 mg/kg subcutaneously or twice-daily doses of moxifloxacin at
48 mg/kg subcutaneously given at 12-hour intervals (total daily dose, 96 mg/kg).
The trovafloxacin dosing regimen was previously shown to result in a significant
reduction in abscess weight and bacterial counts in this model (23). The moxi-
floxacin doses were the maximum that could be injected subcutaneously in mice
and, for comparison, were given twice daily due to the shorter half-life of this
fluoroquinolone in mice compared to trovafloxacin (21, 23). Control mice re-
ceived injections of pyrogen-free saline. Abscess weights, bacterial counts, and
histology were assessed 3, 8, or 14 days after inoculation as outlined in the section
on outcome assessments.
Treatment regimen of abscesses induced by B. fragilis and different E. coli
strains varying in virulence. To ascertain the influence of the severity of the
infection on the efficacy of rmG-CSF with and without moxifloxacin treatment,
mice were inoculated with the same B. fragilis strain combined with either E. coli
ATCC 25922 (n  4) or the more virulent E. coli strains ATCC 35218 (n  10)
and B14349 (n 10). Mice were given rmG-CSF prophylaxis with or without the
moxifloxacin therapy outlined above, which was administered on days 1 to 5 after
inoculation. Mouse survival was checked daily, and abscess, spleen, and blood
bacterial counts were determined on day 1 (three mice per group) and on day 6
(all surviving mice) of infection.
Outcome assessments. On different days of infection blood samples were
obtained by orbital or heart puncture and the leukocytes were counted in a
Coulter Counter (Coulter Electronics, Mijdrecht, The Netherlands). The total
numbers of granulocytes, lymphocytes, and monocytes per ml were calculated
from the total number of leukocytes per ml and the differential counts of 200
leukocytes in Giemsa-stained blood smears.
Mice were killed by CO2 asphyxiation and the abscesses were dissected,
weighed, and homogenized in 1 ml phosphate-buffered saline for 10 seconds (Pro
200, B.V. Centraal Magazijn, Abcoude, The Netherlands). Bacterial counts were
performed on the resulting suspensions by making duplicate serial 10-fold dilu-
tions in phosphate-buffered saline and plating 20 l of each dilution onto EM
agar (E. coli) or WC agar containing 100 mg/liter gentamicin (B. fragilis). Plates
were incubated at 37°C aerobically for 24 h (EM agar) or anaerobically for 48 h
(WC agar).
In experiments comparing combinations of B. fragilis with different E. coli
strains varying in virulence, spleen and blood bacterial counts were also deter-
mined.
For histology of established abscesses, the abscesses from at least two mice per
group (including a section of surrounding skin) were removed on days 3, 8, and
14 after inoculation, fixed in 10% buffered formaldehyde, and embedded in
paraffin. Sections of 5 m were cut on a microtome and mounted on slides.
Preparations were deparaffinized in two changes of xylene, hydrated, and stained
with Goldner’s trichrome or hematoxylin/eosin stains.
Cytokine assays. Blood was collected on different days by orbital or heart
puncture in EDTA tubes, centrifuged 5 min at 7,500  g, and the plasma was
stored at 20°C until measured. Tumor necrosis factor alpha (TNF-) was
determined by a specific radioimmunoassay described previously (12) and had a
detection limit of 40 pg/ml. Interleukin-6 (IL-6) and IL-10 concentrations were
measured using an enzyme-linked immunosorbent assay kit (Biosource Europe)
according to the manufacturer’s instructions. The detection limits were 150 and
8 pg/ml, respectively.
Statistical analysis. Survival between experimental groups and controls was
compared by the log-rank test (Graph Pad software Inc., San Diego, CA).
Abscess weights and bacterial counts are given as the means  standard error of
the mean. The Mann-Whitney test was used to compare differences between two
groups. To analyze the differences between three or more groups, the Kruskal-
Wallis one-way analysis of variance was used with the Tukey-Kramer multiple
comparison as posttest. A P value (two-sided) of  0.05 was considered signif-
icant. Experiments were carried out two to three times, and the data represent
the average results of all experiments performed.
RESULTS
MICs. The MIC of trovafloxacin against the B. fragilis and
the low-virulence E. coli (ATCC 25922) strain was 0.25 and
0.06 g/ml, respectively (24). The MIC of moxifloxacin against
the B. fragilis strain was 0.5 g/ml and against E. coli strains
ATCC 25922, ATCC 35218, and B14349 was 0.125, 0.06 and
0.125 g/ml, respectively.
Treatment of established abscesses with fluoroquinolones
alone. Consistent with our previous report (23), a 5-day treat-
ment regimen of trovafloxacin (150 mg/kg on days 3 to 7 of
infection) significantly reduced bacterial counts and abscess
weights compared with saline-treated controls. Moxifloxacin
was even more effective than trovafloxacin in reducing the
counts of both bacterial strains (P 0.05; Table 1) although, in
contrast, it did not significantly reduce the weight of abscesses
8 days after inoculation (Table 1). Unlike trovafloxacin (23),
moxifloxacin demonstrated no visible toxic effects with the
doses administered. Cytokine concentrations of TNF-, IL-10,
and IL-6 of all groups were around the detection limit (data
not shown).
Effect of rmG-CSF on established abscesses. The number of
circulating granulocytes at the time of inoculation was 0.35 
109 0.03 109/liter in untreated mice and 1.4 109 0.02
109/liter (P  0.057) in mice given 1 g of rmG-CSF prophy-
laxis 24 h earlier, indicating that rmG-CSF was biologically
active. On day 1 of infection, the granulocyte numbers in con-
trol mice had not changed (0.93  0.3  109/liter) and re-
mained stable until day 8 (1.78  0.8  109/liter, P 	 0.05). In
mice that had received rmG-CSF prophylaxis, the granulocyte
response throughout the infection paralleled that of the con-
trol mice, with no significant differences observed.
Both rmG-CSF prophylaxis and rmG-CSF therapy (1 g
daily, days 3 through 7 of infection) did not beneficially influ-
ence the bacterial counts in the abscesses (Table 1). Histolog-
ical examination of untreated abscesses 8 days after inocula-
tion revealed a collagen capsule surrounding an abscess core
comprising large numbers of granulocytes and cell debris. A
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layer of macrophages was evident immediately under the ab-
scess capsule. Abscesses of mice pretreated with rmG-CSF
prophylaxis showed a deeper macrophage layer and a greater
number of macrophages than in control abscesses. In contrast,
in abscesses of mice treated with rmG-CSF therapy, very few
macrophages were seen although, compared to controls, there
was a greater number of granulocytes both within and sur-
rounding the abscesses and more cell debris was present in the
abscess core.
Circulating cytokine concentrations of TNF-, IL-10, and
IL-6 of all groups were around the detection limit (data not
shown).
Treatment of established abscesses with fluoroquinolones
and rmG-CSF. The addition of rmG-CSF prophylaxis to the
trovafloxacin therapy did not enhance the beneficial effect of
trovafloxacin treatment alone (Table 1). To determine whether
rmG-CSF prophylaxis would demonstrate a posttreatment syn-
ergistic effect, abscesses were also examined 7 days after the
termination of trovafloxacin therapy. Although the killing of E.
coli was minimally enhanced compared to trovafloxacin ther-
apy alone (3.1  0.4 versus 3.8  0.3 log10 CFU/abscess, P 
0.01), the addition of rmG-CSF prophylaxis to trovafloxacin
had no significant synergistic effect on B. fragilis numbers or
abscess weights 14 days after inoculation compared to trova-
floxacin alone. To assess if rmG-CSF prophylaxis could im-
prove the efficacy of less effective trovafloxacin doses (23),
subgroups of mice were also treated with doses of 37.5 mg/kg.
Prophylaxis with rmG-CSF failed to enhance the efficacy of
these reduced trovafloxacin doses, since E. coli and B. fragilis
counts were similar in both treated and control abscesses on
day 8 or 14 (data not shown).
RmG-CSF therapy had no synergistic effect on abscess
weights or B. fragilis counts but it did have a significant adverse
effect on the killing of E. coli by trovafloxacin (5.5  0.1 versus
4.9  0.1 log10 CFU/abscess for trovafloxacin alone, P  0.05,
Table 1).
The addition of rmG-CSF prophylaxis or therapy to moxi-
floxacin treatment had no synergistic or antagonistic effect on
abscess weights and bacterial counts.
All cytokine concentrations of TNF-, IL-10, and IL-6 of all
groups of mice were around the detection limit and no differ-
ences between groups were observed (data not shown).
Abscess model with B. fragilis and E. coli strains varying in
virulence and survival rates. On day 1 after inoculation with
107 CFU B. fragilis and 105 CFU E. coli ATCC 25922, the
low-virulence E. coli strain, mice displayed normal activity.
Abscess weights were 31.5  2.5 mg and B. fragilis and E. coli
bacterial counts were 8.4  0.1 and 8.6  0.1 log10 CFU/
abscess, respectively (Table 2). Both strains had disseminated
to the spleen (3.9  0.4 and 4.2  0.4 log10 CFU/spleen,
respectively), but were not isolated from blood samples taken
at the same time. On the other hand, 24 h after inoculation
with combinations containing the virulent hemolytic E. coli
strain ATCC 35218 (103 CFU) or the virulent nonhemolytic E.
coli B14349 (105 CFU), the mice appeared ill and were weak
and lethargic, and both virulent E. coli strains could be cul-
tured from the blood of all mice examined (Table 2). Abscess
and spleen bacterial counts were similar to those of mice in-
oculated with B. fragilis and E. coli ATCC 25922.
No circulating TNF- concentrations were detected 24 h
after inoculation and no significant differences between IL-10
concentrations were observed (Table 2).
Figure 1 shows the effect of the different B. fragilis/E. coli
combinations on mouse survival. Within 3 days of inoculation
with the virulent hemolytic E. coli ATCC 35218 or the virulent
nonhemolytic E. coli B14349, mouse survival was reduced to
20% and 60%, respectively, compared to 100% for the com-
bination with the low-virulence E. coli ATCC 25922. By day 4
of infection, only 10% of mice inoculated with the virulent
hemolytic E. coli strain ATCC 35218 had survived the infec-
tion.
Treatment of abscesses induced by B. fragilis and E. coli
strains varying in virulence with rmG-CSF and fluoroquino-
lones. In mice inoculated with B. fragilis and the virulent he-
molytic E. coli strain ATCC 35218, treatment with moxifloxa-
cin that started 24 h after inoculation had a significant effect on
mouse survival (75% versus 10%, P  0.0001; Fig. 2A) com-
pared to saline-treated controls. This beneficial effect of moxi-
floxacin was associated with significantly reduced bacterial
counts of both B. fragilis and E. coli in mice that had survived
TABLE 1. Effect of rmG-CSF, with or without trovafloxacin or moxifloxacin treatment, on established B. fragilis ATCC 23745/low-virulence
E. coli ATCC 25922 abscesses 8 days after inoculationa
rmG-CSF Abscess parameter
Treatment (days 3 to 7)
Saline Trovafloxacin(150 mg/kg daily)
Moxifloxacin
(48 mg/kg twice a day)
None Weight (mg  SEM) 74  5 44  3b 69  4
E. coli (log10 CFU/abscess  SEM) 7.4  0.1 4.9 0.1
b 4.2  0.1b,c
B. fragilis 8.7  0.1 6.9 0.4b 5.8  0.1b,c
Prophylaxis 1,000 ng
daily on day 1
Weight 60 4 45  3b 70  5
E. coli 7.4  0.0 4.7 0.2b 3.8  0.1b,c
B. fragilis 8.7  0.0 7.1 0.3b 6.5  0.2b
Therapy 1,000 ng daily
on days 3 to 7
Weight 83 8 53  6b 70  15
E. coli 7.6  0.1 5.5 0.1b,d 4.3  0.2b,c
B. fragilis 8.9  0.1 7.6 0.2b 5.9  0.2b,c
a P values are shown as follows: bsignificantly different from respective saline-treated group (P  0.05); csignificantly different from respective trovafloxacin-treated
group (P  0.05); dsignificantlly different from group treated with trovafloxacin alone (P  0.05).
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on day 6 of infection (Fig. 3B). rmG-CSF prophylaxis did not
influence survival of mice compared to control mice, however,
the addition of rmG-CSF prophylaxis to the moxifloxacin treat-
ment significantly reduced mouse survival compared to the
group given moxifloxacin alone (30% versus 75%, P  0.005;
Fig. 2A). The detrimental influence of rmG-CSF prophylaxis
in mice was accompanied by a threefold (virulent hemolytic E.
coli strain) and 100-fold (B. fragilis, P  0.05) increased out-
growth in the abscesses of mice that had survived on day 6 of
infection and were treated with rmG-CSF and moxifloxacin
compared to moxifloxacin treatment alone (Fig. 3B).
In contrast, addition of rmG-CSF prophylaxis to moxifloxa-
cin treatment did not have a detrimental influence on the
survival of mice inoculated with B. fragilis and the virulent
nonhemolytic E. coli strain B 14349 (Fig. 2B), nor did it det-
rimentally influence the bacterial counts in abscesses of mice
that had survived on day 6 of infection (Fig. 3C).
Six days after inoculation and compared to saline-treated
FIG. 1. Survival of mice inoculated subcutaneously with mixtures
comprising B. fragilis (107 CFU) and either low-virulence E. coli strain
ATCC 25922 (105 CFU) or the more virulent strain ATCC 35218 (103
CFU) or B14349 (105 CFU).
FIG. 2. Effect of rmG-CSF prophylaxis (1,000 ng on day 1), with
or without moxifloxacin treatment (96 mg/kg/day) on the survival
of mice inoculated with mixtures comprising B. fragilis (107 CFU) and
the more virulent E. coli strains (A) ATCC 35218 (103 CFU) and
(B) B14349 (105 CFU).
TABLE 2. Comparison of abscess and mouse parameters 24 h after inoculation with mixtures comprising B. fragilis with
E. coli strains varying in virulence
Determination Parametera
E. coli strain (CFU)
Low-virulence ATCC
25922 (105)
Virulent hemolytic
ATCC 35218 (103)
Virulent nonhemolytic
B14349 (105)
Abscess Weight 31.5 3 31.8  3 19.3  1.3
E. coli 8.6  0.1 8.2  0.1 8.9  0.0
B. fragilis 8.4  0.1 8.2  0.0 8.4  0.1
Spleen E. coli 4.2  0.4 4.8  0.3 4.2  0.4
B. fragilis 3.9  0.4 3.4  0.5 3.2  0.6
Blood E. coli 0.5 1.0  0.5b 2.4  0.3b
B. fragilis 0.5 0.5 0.5
Cytokines (pg/ml) TNF 40 40 40
IL-10 60 12 72  11 37  8
a Weights, mg  SEM; bacterial counts, log10 CFU/abscess (spleen)  SEM.
b Bacteremia was present in 3/3 mice.
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controls, moxifloxacin treatment significantly reduced both B.
fragilis and E. coli bacterial counts in abscesses containing the
low-virulence E. coli ATCC 25922 (Fig. 3A). Administration of
rmG-CSF prophylaxis alone significantly reduced low-viru-
lence E. coli abscess bacterial counts and had a significant
synergistic effect on the killing of the low-virulence E. coli
strain by moxifloxacin (Fig. 3A).
In the surviving mice of all groups, moxifloxacin significantly
reduced the bacterial counts in the spleens by 1.5 to 4.2 log10
CFU/spleen compared to saline-treated controls and addition
FIG. 3. Effect of rmG-CSF prophylaxis (1,000 ng on day 1), with or without moxifloxacin treatment (96 mg/kg/d days 1 to 5) on abscess
bacterial counts 6 days after inoculation with combinations comprising B. fragilis and E. coli strain (A) ATCC 25922, (B) ATCC 35218, or
(C) B14349. Horizontal bars indicate the means. a, P  0.01 compared to saline-treated controls; b, P  0.05 compared to the group treated with
moxifloxacin alone.
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of rmG-CSF prophylaxis did not alter the effect of moxifloxacin
(P  0.05) (results not shown). The observed differences in
survival between the groups could not be explained by differ-
ences in circulating concentrations of TNF- (all below the
detection limit) or IL-10 (all around 17 pg/ml).
Macroscopic abscess appearance in surviving mice. In mice
surviving to day 6, there were visible differences in the external
and internal appearance of the abscesses that developed from
the three inocula combinations. Externally, E. coli ATCC
25922 abscesses formed a “ball-shaped” swelling (measuring
approximately 9 by 7 mm) protruding from under the skin on
both flanks of the animals. There was no necrosis of the over-
lying skin and, internally, the pus of the abscess was very easy
to remove.
In contrast, the abscesses of mice surviving the virulent he-
molytic E. coli ATCC 35218 infection (including those treated
with rmG-CSF and/or moxifloxacin) were not protuberant and
had spread over a wide area (approximately 10 by 15 mm).
Necrosis of the overlying skin was found in 89% (41 of 46) of
the abscesses. Internally, the pus appeared as a thickened cap-
sule, making the abscesses more difficult and, in some cases,
impossible to remove. In some animals (four mice), the ab-
scesses on both flanks of the mice had merged together form-
ing one large abscess and could not, therefore, be included in
bacterial count determinations. A total of 26 abscesses were
cultured.
Necrosis of the overlying skin was found in 52% (29 of 56) of
abscesses containing the virulent nonhemolytic E. coli B14349.
Although these abscesses were similar in size and appearance
to those with the low-virulence E. coli ATCC 25922 strain,
internally a thickened capsule had formed, making these ab-
scesses also more difficult or impossible to remove. A total of
28 abscesses were cultured.
DISCUSSION
This study demonstrated the efficacy of both trovafloxacin
and moxifloxacin in reducing B. fragilis and low-virulence E.
coli numbers in established abscesses, with moxifloxacin being
the most potent agent. The addition of rmG-CSF prophylaxis
or therapy provided no further beneficial effect to fluoroquin-
olone treatment of established abscesses. In contrast, in our
model with the virulent hemolytic E. coli strain, addition of
rmG-CSF antagonized the effect of moxifloxacin therapy, as
indicated by reduced survival and increased outgrowth of bac-
teria in the abscesses.
Moxifloxacin was more efficacious than trovafloxacin in re-
ducing established abscess bacterial counts 8 days after inocu-
lation with B. fragilis and low-virulence E. coli ATCC 25922.
This occurred despite the fact that the MICs of moxifloxacin
against both bacterial strains were higher, lower daily doses of
moxifloxacin were administered, and the AUC0-24 h for moxi-
floxacin in mice is lower (21, 23). Consequently, our results
suggest that, in this animal model at least, moxifloxacin is more
potent than trovafloxacin. Previous studies have shown that the
activities of both trovafloxacin and moxifloxacin are unaffected
by dead bacteria, albumin globulin, pus, or anaerobic condi-
tions (17). It is unlikely, therefore, that the activity of trova-
floxacin was affected by the adverse conditions present in the
abscesses and the superior activity of moxifloxacin may be due
to its lower protein binding (21, 23).
Interestingly, trovafloxacin reduced the weights of the estab-
lished abscesses, whereas moxifloxacin treatment did not. In
our previous study, it was suggested that the reduction in B.
fragilis numbers and concomitant reduction in inflammation
was responsible for the decreased abscess weights (23). How-
ever, in the present study, B. fragilis counts in abscesses of
moxifloxacin-treated mice were significantly reduced com-
pared to those in abscesses of trovafloxacin-treated mice. Thus,
it is more likely that bacterial degradation products, due to the
increased or different killing capacity of moxifloxacin com-
pared to trovafloxacin, induced a strong proinflammatory re-
sponse that resulted in increased abscess weights. Moreover,
this indicates that a reduction of bacterial numbers does not
necessarily coincide with a diminished inflammatory response.
Alternatively, the influence on abscess weights may be the
consequence of differences in the immunomodulatory capacity
of the two fluoroquinolones.
Both trovafloxacin and moxifloxacin play a dual role in in-
fections, an antimicrobial role and an immunomodulatory role
by inhibiting lipopolysaccharide-stimulated secretion of IL-1,
IL-1
, and TNF- by monocytes (2, 8). However, both fluoro-
quinolones differ with respect to the additional structures that
are placed at the 1 position of the quinolone ring. Moxifloxacin
has a cyclopropyl moiety at position 1 of the quinolone ring,
whereas trovafloxacin does not. Only quinolones with the cy-
clopropyl group are able to stimulate white-blood-cell produc-
tion (4), and moxifloxacin has been shown to significantly ame-
liorate the white-blood-cell and neutrophil counts of
cyclophosphamide-injected mice (20). Thus, it is likely that by
increasing the amount of granulocytes, moxifloxacin has an
additional beneficial immunomodulating property compared
to trovafloxacin. If this was indeed true, then the addition of
rmG-CSF to (reduced amounts of) trovafloxacin would raise
the level of treatment to moxifloxacin levels and increase ab-
scess weights. However, this was not the case on day 8 of
infection. In fact, addition of rmG-CSF to fluoroquinolone
therapy did not have any beneficial effect and moxifloxacin
treatment alone was superior.
Although rmG-CSF did not influence bacterial counts on
day 8 of infection, 7 days after inoculation with B. fragilis/low-
virulence E. coli ATCC 25922, rmG-CSF prophylaxis signifi-
cantly reduced E. coli bacterial counts and, combined with
moxifloxacin treatment, improved the efficacy of the fluoro-
quinolone against the E. coli strain. This indicates that we
either assessed bacterial outgrowth at the wrong time point or,
at best, the beneficial and synergistic effects of rmG-CSF ap-
peared to be transient. This is corroborated by a previous study
that also reported a similar temporary antibacterial effect of
G-CSF in an endocarditis infection model (25). Furthermore,
although rmG-CSF displayed a posttreatment synergistic effect
on the low-virulence E. coli strain 14 days after inoculation, we
are cautious in drawing any conclusions from these findings
due to the increased range in bacterial counts at this stage of
abscess development and, therefore, the limitations of this
animal model.
Quinolones readily accumulate in granulocytes and enhance
intracellular killing mechanisms (13–15). Therefore, it was as-
sumed that, by increasing the numbers of granulocytes follow-
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ing rmG-CSF treatment, these cells would contribute to
achieving higher drug concentrations in the abscesses by serv-
ing as secondary transport systems for the fluoroquinolones. In
our experiments, however, these putative effects have not led
to synergistic effects of rmG-CSF and quinolones. In addition,
because TNF- and IL-1 are important activators of granulo-
cyte function (19, 29), the presence of fluoroquinolones might
suppress polymorphonuclear neutrophil function as they have
been shown to reduce secretion of these cytokines (2, 8). Also,
the absence of synergy may have been due to inhibited neu-
trophil function within the abscesses (1, 5).
Depending on the severity of the infection, rmG-CSF pro-
phylaxis could detrimentally affect the efficacy of moxifloxacin.
In our model with the more virulent hemolytic E. coli ATCC
35218, rmG-CSF prophylaxis reduced mouse survival which
was accompanied by a threefold (E. coli) and 100-fold (B.
fragilis) increased outgrowth in abscesses compared to mice
treated with moxifloxacin alone. This negative effect of rmG-
CSF is in line with previous research showing a detrimental in-
fluence of G-CSF on survival from E. coli sepsis (16), E. coli
pneumonia (7), and on antibiotic treatment of E. coli peritonitis
(18). The endotoxin released after moxifloxacin treatment might
have induced an increase in circulating TNF- concentrations.
Surprisingly, however, no correlation between circulating TNF-
concentrations and mortality was observed. Possibly the TNF-
concentrations were not increased due to the down-regulatory
influence of the fluoroquinolones and G-CSF (6, 10).
Since the abscesses of mice surviving the virulent hemolytic
E. coli infection had spread over a wide area, i.e., no optimal
compartmentalization occurred, rmG-CSF-stimulated granu-
locytes may have increased the detrimental effect of the in-
flammatory process, leading to greater numbers of bacteria in
the bloodstream and organs. Furthermore, G-CSF has been
shown to increase CD14 expression in response to endotoxin,
which results in up-regulation of adherence receptors on granu-
locytes (28). In addition, hemolysins produced by thisE. coli strain
may have worsened outcome of infection by inducing reactive
oxygen metabolites and proinflammatory mediators (9).
In conclusion, the administration of G-CSF, either prophy-
lactically before the formation of abscesses or during fluoro-
quinolone treatment of established abscesses, is not considered
beneficial. Depending on the severity of infection caused by
differences in virulence of the E. coli strains, the administration
of G-CSF prophylaxis in conjunction with fluoroquinolones
can impair the outcome compared to fluoroquinolone treat-
ment alone.
ACKNOWLEDGMENT
This study was financially supported by Pfizer BV, Cappelle a/d
Ijssel, The Netherlands.
REFERENCES
1. Abdul-Majid, K. B., P. A. Kenny, and J. J. Finlay-Jones. 1997. The effect of
the bacterial product, succinic acid, on neutrophil bactericidal activity.
FEMS Immunol. Med. Microbiol. 17:79–86.
2. Araujo, F. G., T. L. Slifer, and J. S. Remington. 2002. Effect of moxifloxacin
on secretion of cytokines by human monocytes stimulated with lipopolysac-
charide. Clin. Microbiol. Infect. 8:26–30.
3. Barsig, J., D. S. Bundschuh, T. Hartung, A. Bauhofer, A. Sauer, and A.
Wendel. 1996. Control of fecal peritoneal infection in mice by colony-stim-
ulating factors. J. Infect. Dis. 174:790–799.
4. Dalhoff, A., and I. Shalit. 2003. Immunomodulatory effects of quinolones.
Lancet 3:359–371.
5. Finlay-Jones, J. J., K. V. L. Davies, L. P. Sturm, P. A. Kenny, and P. H. Hart.
1999. Inflammatory processes in a murine model of intra-abdominal abscess
formation. J. Leukoc. Biol. 66:583–587.
6. Gorgen, I., T. Hartung, M. Leist, M. Niehorster, G. Tiegs, S. Uhlig, F.
Weitzel, and A. Wendel. 1992. Granulocyte colony-stimulating factor treat-
ment protects rodents against lipopolysaccharide-induced toxicity via sup-
pression of systemic tumor necrosis factor-alpha. J. Immunol. 149:918–924.
7. Karzai, W., B. U. von Specht, C. Parent, J. Haberstroh, K. Wollersen, C.
Natanson, S. M. Banks, and P. Q. Eichacker. 1999. G-CSF during Esche-
richia coli versus Staphylococcus aureus pneumonia in rats has fundamentally
different and opposite effects. Am. J. Respir. Crit. Care Med. 159:1377–1382.
8. Khan, A. A., T. L. Slifer, and J. S. Remington. 1998. Effect of trovafloxacin
on production of cytokines by human monocytes. Antimicrob. Agents Che-
mother. 42:1713–1717.
9. Konig, B., W. Konig, J. Scheffer, J. Hacker, and W. Goebel. 1986. Role of
Escherichia coli alpha-hemolysin and bacterial adherence in infection: re-
quirement for release of inflammatory mediators from granulocytes and
mast cells. Infect. Immun. 54:886–892.
10. Lundblad, R., J. M. Nesland, and K.-E. Giercksky. 1996. Granulocyte col-
ony-stimulating factor improves survival rate and reduces concentrations of
bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant
intra-abdominal sepsis in rats. Crit. Care Med. 24:820–826.
11. McClean, K. L., G. J. Sheehan, and G. K. M. Harding. 1994. Intra-abdom-
inal Infection: a review. Clin. Infect. Dis. 19:100–116.
12. Netea, M. G., P. N. Demacker, B. J. Kullberg, O. C. Boerman, I. Vers-
chueren, A. F. Stalenhoef, and J. W. van der Meer. 1996. Low-density
lipoprotein receptor-deficient mice are protected against lethal endotoxemia
and severe gram-negative infections. J. Clin. Investig. 97:1366–1372.
13. Nielsen, S. L., N. Obel, M. Storgaard, and P. L. Andersen. 1997. The effect
of quinolones on the intracellular killing of Staphylococcus aureus in neutro-
phil granulocytes. J. Antimicrob. Chemother. 39:617–622.
14. Pascual, A., I. Garcia, S. Ballesta, and E. J. Perea. 1999. Uptake and
intracellular activity of moxifloxacin in human phagocytes and tissue-cul-
tured epithelial cells. Antimicrob. Agents Chemother. 43:12–15.
15. Pascual, A., I. Garcia, S. Ballesta, and E. J. Perea. 1997. Uptake and
intracellular activity of trovafloxacin in human phagocytes and tissue-cul-
tured epithelial cells. Antimicrob. Agents Chemother. 41:274–277.
16. Quezado, Z., C. Parent, W. Karzai, M. Depietro, C. Natanson, W. Ham-
mond, R. L. Danner, X. Cui, Y. Fitz, S. M. Banks, E. Gerstenberger, and
P. Q. Eichacker. 2001. Acute G-CSF therapy is not protective during lethal
E. coli sepsis. Am. J. Physiol. Regulatory Integrative Comp. Physiol. 281:
R1177–R1185.
17. Rubinstein, E., L. Diamantstein, G. Yoseph, G. Gruzman, B. Rubinovitch, A.
Barzilai, and N. Keller. 2000. The effect of albumin globulin, pus and dead
bacteria in aerobic and anaerobic conditions on the antibacterial activity of
moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneu-
moniae, Staphylococcus aureus and E. coli. Clin. Microbiol. Infect. 6:675–686.
18. Saba, R., M. Guler, D. Inan, D. Ogunc, S. Atalay, L. Mamikoglu, and F.
Gunseren. 2003. The effect of granulocyte colony-stimulating factor in the
treatment of Escherichia coli peritonitis with or without ceftriaxone in a
nonneutropenic rat model. Surg. Today 33:504–508.
19. Shalaby, M. R., B. B. Aggarwal, E. Rinderknecht, L. P. Sverdersky, B. S.
Finkle, and J. Palladino. 1985. Activation of human polymorrphonuclear
neutrophil functions by interferon-gamma and tumor necrosis factors. J. Im-
munol. 135:2069–2073.
20. Shalit, I., Y. Kletter, D. Halperin, D. Waldman, E. Vasserman, A. Nagler,
and I. Fabian. 2001. Immunomodulatory effects of moxifloxacin in compar-
ison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-
induced leukopenia. Eur. J. Haematol. 66:287–296.
21. Siefert, H. M., A. Domdey-Bette, K. Henninger, F. Hucke, C. Kohlsdorfer,
and H. H. Stass. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxi-
floxacin: a comparison in humans and other mammalian species. J. Antimi-
crob. Chemother. 43(Suppl. B):69–76.
22. Stearne, L. E. T., S. L. Buijk, J. W. Mouton, and I. C. Gyssens. 2002. Effect
of a single percutaneous abscess drainage puncture and imipenem therapy,
alone or in combination, in treatment of mixed-infection abscesses in mice.
Antimicrob. Agents Chemother. 46:3712–3718.
23. Stearne, L. E. T., I. C. Gyssens, W. H. Goessens, J. W. Mouton, W. J. Oyen,
J. W. van der Meer, and H. A. Verbrugh. 2001. In vivo efficacy of trovafloxa-
cin against Bacteroides fragilis in mixed infections with either Escherichia coli
or a vancomycin-resistant strain of Enterococcus faecium in an established-
abscess murine model. Antimicrob. Agents Chemother. 45:1394–1401.
24. Stearne, L. E. T., C. Kooi, W. H. Goessens, I. A. J. M. Bakker-Woudenberg,
and I. C. Gyssens. 2001. In vitro activity of trovafloxacin against Bacteroides
fragilis in mixed culture with either Escherichia coli or a vancomycin resistant
strain of Enterococcus faecium using an anaerobic time kill technique. An-
timicrob. Agents Chemother. 45:243–251.
25. Vignes, S., B. Fantin, C. Elbim, F. Walker, M.-A. Gougerot-Pocidalo, and C.
Carbon. 1995. Critical influence of timing of administration of granulocyte
colony-stimulating factor on antibacterial effect in experimental endocarditis
due to Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:2702–2707.
26. Villa, P., L. Shaklee, C. Meazza, D. Agnello, P. Ghezzi, and G. Sendaldi.
3674 STEARNE ET AL. ANTIMICROB. AGENTS CHEMOTHER.
1998. Granulocyte colony-stimulating factor and antibiotics in the prophy-
laxis of a murine model of polymicrobial peritonitis and sepsis. J. Infect. Dis.
178:471–477.
27. Vonk, A. G., M. G. Netea, J. H. van Krieken, P. E. Verweij, J. W. van der
Meer, and B. J. Kullberg. 2003. Treatment of intra-abdominal abscesses
caused by Candida albicans with antifungal agents and recombinant murine
granulocyte colony-stimulating factor. Antimicrob. Agents Chemother. 47:
3688–3693.
28. Wright, S. D., R. A. Ramos, A. Hermanowski-Vosatka, P. Rockwell, and P. A.
Detmers. 1991. Activation of the adhesive capacity of CR3 on neutrophils by
endotoxin: dependence on lipopolysaccharide binding protein and CD14. J.
Exp. Med. 173:1281–1286.
29. Yagisawa, M., A. Yuo, S. Kitagawa, Y. Yazaki, and F. Takaku. 1995. Stim-
ulation and priming of human neutrophils by IL-1 alpha and IL-1 beta:
complete inhibition by IL-1 receptor antagonist and no interaction with
other cytokines. Exp. Hematol. 23:603–608.
VOL. 49, 2005 G-CSF AND FLUOROQUINOLONES IN AN ABSCESS MODEL 3675
